| In vivo Pharmacology (3)

PDE 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease

Posted by Evotec on Mar 2, 2021 1:04:43 PM

0 Comments Click here to read/write comments

Tags: Neuroscience, Articles & Whitepapers, In vivo Pharmacology

Characterization of HTT in the zQ175 Mouse Model of Huntington´s Disease

Posted by Evotec on Mar 2, 2021 12:51:32 PM

0 Comments Click here to read/write comments

Tags: Articles & Whitepapers, In vivo Pharmacology

In Vivo Efficacy of Peptide SPR741 in Gram Negative Bacterial Infection

Posted by Evotec on Feb 24, 2021 1:16:32 PM

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology

Efficacy of BAL30072 on Resistant Gram Negative Bacteria

Posted by Evotec on Feb 24, 2021 1:13:39 PM

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology, Anti-Infectives

In Vitro and In Vivo Characterization of FG-630 LpxC Inhibitor

Posted by Evotec on Feb 24, 2021 12:47:15 PM

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology, Anti-Infectives

In Vivo Efficacy of Novel Antimicrobial Peptide Spr741 and Rifampicin

Posted by Evotec on Feb 24, 2021 12:37:55 PM

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology, Anti-Infectives

Effects of Theophylline and Budesonide on Asthma Inflammation Model

Posted by Evotec on Feb 24, 2021 12:00:51 PM

0 Comments Click here to read/write comments

Tags: Respiratory, Posters, In vivo Pharmacology

Optimised Conditions for Measuring OX1 Receptor Occupancy

Posted by Evotec on Feb 20, 2021 8:07:55 PM

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology

PKPD Models for Antibiotic Efficacy

Posted by Evotec on Feb 15, 2021 10:35:36 AM

Pharmacokinetic/pharmacodynamic (PK/PD) modelling plays an important role in drug development, especially in the case of antibiotics where the data generated is used for dose prediction up to Phase 2 clinical trials. This enables efficient study designs and identification of optimal dosing regimens that may suppress drug resistance.

In this poster, we focus on:

mathematical modelling of in vivo and in vitro data to generate a rational design with reduced animal requirements in order to determine the pharmacodynamic driver and magnitude of antibiotic efficacy
optimisation of the clinical dose regimen in Phase 2 clinical trials

Read our poster to learn more about our research!

0 Comments Click here to read/write comments

Tags: Posters, In vivo Pharmacology

Previous All posts